Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 4Phase NA 2Phase 3 2Phase 1/2 2Phase 4 1

Status

Recruiting 10Completed 7Active not recruiting 7Not yet recruiting 4Unknown 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 28Cisplatin 28Carboplatin 27Capecitabine 27camrelizumab 25Nivolumab 24apatinib 23Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 19Drug Therapy 18Immunotherapy, Adoptive 17pembrolizumab 16Docetaxel 16Bevacizumab 16Dexamethasone 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12Fluorouracil 11130-nm albumin-bound paclitaxel 11anlotinib 10Trastuzumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × osimertinib × Clear all
NCT05498389 2023-06-01

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Shanghai EpimAb Biotherapeutics Co., Ltd.

Phase 1/2 Unknown
115 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05284994 2022-03-17

TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Unknown
160 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡